Your browser doesn't support javascript.
loading
Análise de sobrevida de pacientes pediátricos portadores de rabdomiossarcoma: 18 anos de experiência do Instituto Nacional de Câncer - RJ / Survival analysis in pediatric patients with rhabdomyosarcoma: 18-year experience at the National Cancer Institute - RJ
São Paulo; s.n; 2005. [132] p. ilus, tab, graf.
Thesis in Portuguese | LILACS | ID: lil-436082
ABSTRACT
Foram analisados 163 pacientes portadores de rabdomiossarcoma tratados no período de 1986 a 2004 quanto ao perfil demográfico, socioeconômico, clínico, biológico e patológico. A mediana de idade foi 4,9 anos (3 m a 16 a). O sítio primário mais freqüente foi cabeça e pescoço n=73 (44,7por cento). A distribuição de grupos clínicos foi I + II (10,4por cento), III (49,1por cento) and IV (39,3por cento). A probabilidade acumulada de sobrevida global e de SLE foi 48,6por cento e 42,2por cento em 60 meses, respectivamente. A SLE foi 73,3 por cento (GC I + II), 57,5 por cento (GC III) e 14,9 por cento (GC IV), p <0,001. Os fatores prognósticos independentes foram faixa etária dos menores de 1 ano (HRaj=3,4; p=0,022) e maior de 10 anos (HRaj= 1,7; p=0,069), ter 1 ou 2 e mais sítios de metástase (respectivamente, HRaj=3,3; p<0,001 e HRaj=6,8; p<0,001) e ter percentil de índice de massa corporal < 10 (HRaj= 2,0; p=0,027) / One hundred and sixty three patients with rhabdomyosarcoma were retrospectively analyzed from 1986 to 2004 for demographic, socioeconomic, clinical, biological and pathological variables. Median age at diagnosis was 4.9 years (range 3 months to 16 years). The most frequent primary site was head and neck in 73 (44.7per cent) patients. Clinical groups (CG) distribution was I + II (10.4 per cent), III (49.1 per cent) and IV (39.3 per cent). Overall survival and EFS in 60 months were 48.6 per cent and 42.2 per cent, respectively. The EFS was 73.3 per cent in CG I + II, 57.5 per cent in GC III and 14.9 per cent in GC IV (p<0.001). The independent prognostic factors were age < 1 year (HRaj=3.4; p=0.022) and > 10 years (HRadj= 1.7; p=0.069), 1 or 2 and more metastatic sites (respectively HRadj=3.3; p<0,001 e HRadj=6.8; p<0.001) and body mass index below the 10th percentile (HRaj= 2.0; p=0.027)...
Subject(s)
Full text: Available Index: LILACS (Americas) Main subject: Prognosis / Rhabdomyosarcoma / Neoplasm Staging Type of study: Prognostic study Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: Portuguese Year: 2005 Type: Thesis

Similar

MEDLINE

...
LILACS

LIS

Full text: Available Index: LILACS (Americas) Main subject: Prognosis / Rhabdomyosarcoma / Neoplasm Staging Type of study: Prognostic study Limits: Adolescent / Child / Child, preschool / Female / Humans / Infant / Male Language: Portuguese Year: 2005 Type: Thesis